Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

Chrysoula Pipili, Evangelos Cholongitas

Chrysoula Pipili, Division of Nephrology, Royal Infirmary of Edinburgh, Scotland EH16 4SA, United Kingdom
Evangelos Cholongitas, 4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece

Author contributions: Pipili C and Cholongitas E contributed equally in writing and editing of the article.

Conflict-of-interest: None.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Evangelos Cholongitas, Assistant Professor of Internal Medicine, 4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, 49, Konstantinopoleos Street, 54642 Thessaloniki, Greece. cholongitas@yahoo.gr
Telephone: +30-23-10892110
Fax: +30-23-10992940

Received: December 13, 2014
Peer-review started: December 13, 2014
First decision: January 8, 2015
Revised: May 18, 2015
Accepted: June 1, 2015
Article in press: June 2, 2015
Published online: June 28, 2015

Abstract

The first generation direct antiviral agents (DAAs) highlighted substantial prognosis improvement among liver transplant (LT) candidates and recipients with recurrent hepatitis C virus (HCV) infection. During 2014, second generation DAAs are associated with high sustained virological response rates (> 95%), shortened duration courses and relatively few toxicities. In keeping with the currently available data, patients with decompensated cirrhosis awaiting LT is preferable to be treated with interferon-free, new generation DAAs, with or without ribavirin combinations. Although data about the safety of new DAAs combinations in this patient population are limited, sofosbuvir and daclatasvir pharmacokinetics do not appear to change significantly in moderate or severe liver impairment, while other new DAAs (simeprevir, asunaprevir) seem to be contraindicated in patients with severe liver impairment (Child-Pugh class C). On the other hand, sofosbuvir should not be given in patients with glomerular filtration rate ≤ 30 mL/min, but ongoing trials will clarify better this issue. With the objective that newer antiviral combinations will yield safer and more efficient manipulation of HCV recurrence post-transplant, the European Association for the Study of the Liver has recently updated its recommendations towards this direction. Nevertheless the new antivirals’ high cost may be the biggest challenge to their implementation worldwide.

Key words: Liver transplantation; Decompensated cirrhosis; Hepatitis C; New antiviral agents; Sofosbuvir; Simeprevir; Daclatasvir; Recurrent hepatitis C

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Treatment landscape for liver transplant (LT) candidates and recipients with chronic hepatitis C is rapidly shifting due to novel updated data on direct antiviral agents (DAAs); Patients with decompensated cirrhosis awaiting LT should be treated with the interferon (IFN)-free, new generation DAAs, with or without ribavirin (RBV) regimens; IFN-free combinations of sofosbuvir with other novel DAAs with or without RBV led to remarkable on-treatment virological response...
INTRODUCTION

Hepatitis C virus (HCV) infection is the leading liver cause of death worldwide and the main indication for liver transplantation (LT)\textsuperscript{[1-3]}. It also diminishes overall and graft survival in LT recipients resulting in shorter survival compared with other LT recipients\textsuperscript{[4,5]}. Ideally, viral load elimination prior to LT hampers graft loss from chronic hepatitis C (CHC) recurrence\textsuperscript{[6]}. In the absence of an HCV vaccine to prevent infection and with therapy until very recently limited to interferon (IFN)-based regimens, most HCV-infected candidates for LT patients remained untreated. Direct antiviral agents (DAAs) represent a striking innovation in HCV treatment. The first generation DAAs, boceprevir and telaprevir, act mainly as NS3-4A serine protease inhibitors and have been in use since 2011. When combined with pegylated IFN (Peg-IFN) and ribavirin (RBV) lead to 30% increase of sustained virological response (SVR) on CHC patients with genotype 1, absolute co-administration with Peg-IFN and RBV, frequent drug-to-drug interactions and toxicity, particularly in patients with underlying cirrhosis\textsuperscript{[7]}. Patients with decompensated cirrhosis who are on the transplant list should be considered for IFN-free, ideally RBV-free therapy because both Peg-IFN and RBV are associated with poor tolerability and many side effects mainly due to the splenomegaly-related pancytopenia\textsuperscript{[8]}. Other classes of DAAs targeting different steps of HCV replication have been approved more recently, including nucleotide polymerase (NUC-NS5B) inhibitors, non-nucleotide polymerase (non-NUC-NS5B) inhibitors and NSSA inhibitors. Several dual and triple DAA regimens are in clinical development in patients before and after LT suggesting that these regimens will dramatically reduce the impact of recurrent HCV post LT\textsuperscript{[8]}. Within 2014, three new DAAs were licensed for use in combined therapies against HCV infection in the European Union. These include sofosbuvir, (Sovaldi, Gilead Sciences) which represents the first NS5B HCV polymerase inhibitor that has pangenotypic antiviral activity and a high genetic barrier to resistance\textsuperscript{[9]}, simeprevir (Olysio, Janssen), a second-wave NS3/4A protease inhibitor; and daclatasvir (Daklinza, BMS), an NS5A inhibitor\textsuperscript{[10]}. In addition, other DAAs are currently under consideration and their final approval is waiting in the first half of 2015 (Table 1). All these DAAs have been evaluated with or without Peg-IFN ± RBV. Although scarce data is available in LT candidates and recipients, novel DAAs combinations seem more efficacious and better-tolerated option. Nevertheless, cost limitations across various health insurances may avert their use. The current review updates treatment for patients with CHC before and after LT.

HCV positive LT candidates

The aim of antiviral therapy before LT is the undetectable HCV RNA at the time of LT or SVR before LT\textsuperscript{[10]}. Peg-IFN and RBV was the standard of care for patients with CHC up to 2011. Indeed they reduced cirrhosis driven complications such as HCC and improved the abnormal histological changes\textsuperscript{[12-16]}, but in an inadequate percentage of patients\textsuperscript{[12-16]}. Generally, SVR rates are lower in patients with cirrhosis ranging 40%-50% for Child-Pugh (CP) class A and 7%-26% for CP class C\textsuperscript{[17-20]} and in patients with genotypes 1 and 4 compared with genotype 2 and 3 patients (51% vs 61%)\textsuperscript{[20]} while a reduction on SVR is evident regarding the level of fibrosis (Tables 2 and 3). Peg-IFN-based treatment has also been associated with poor tolerability and lots of adverse effects\textsuperscript{[12-16]}. These include neuropsychiatric disorders and mainly pancytopenia\textsuperscript{[20]}, requiring erythropoietin and granulocyte colony- stimulating factors\textsuperscript{[21,22]},. Of note, LT candidates with HCV compensated cirrhosis are more prone to Peg-IFN- and RBV-related hematologic toxicities, because splenomegaly caused by portal hypertension enhances the risk for cytopenias\textsuperscript{[23]}. Therefore, Peg-IFN and RBV dose adjustment and close monitoring is recommendable. More specifically, patients with CP score B require treatment tailoring decisions focused on type of genotype, level of viral load and first or repeat antiviral treatment\textsuperscript{[10]}. A triple therapy with the addition of first generation DAAs is the preferred choice for patients with genotype 1 when newer DAAs are not available\textsuperscript{[23]}. Boceprevir and telabrevir are better therapeutic choice for patients with genotype 1 ensuring excellent efficacy and prognosis compared to Peg-IFN and RBV treatment. Data showed that triple therapy increased SVR rates in naive and previously treated patients with genotype 1 between 68%-75% and 59%-88% respectively\textsuperscript{[24-28]}. Boceprevir therapy also offers the possibility of shortened duration therapy for rapid responders, defined by an undetectable plasma HCV RNA level at treatment week 8\textsuperscript{[24]}. One should notice that DAAs should not be applied as monotherapy and their dose should not be reduced,
stopped and then restarted\[^{29}\]. However, high rates of serious adverse events, discontinuation and deaths have been recorded\[^{30}\]. The adverse effects included anaemia, metallic taste, infection and rash which were more evident in patients with cirrhosis\[^{24-28}\]. For this reason the administration of the triple therapy remains of high risk in patients with cirrhosis.Anaemia is considered positive predictor of SVR in patients receiving the triple regimen and should be corrected with erythropoietin and reduction of RBV dose\[^{31-33}\] without any change in boceprevir or telaprevir administration. The data regarding the efficacy and safety of triple therapy to HCV patient with decompensated cirrhosis are very limited. Verna et al\[^{34}\] treated 29 patients with cirrhosis CP class A (62%) or B (38%) while waiting on the transplant list with telaprevir (93%) or boceprevir-based (7%) triple therapy for a median (range) of 27 (3-50) wk, including a Peg-IFN and RBV lead-in phase in 18%. Overall SVR at 12 wk was 52%, including patients who completed a full course of therapy, but 28% of patients require hospital admission because of treatment complications including decomposition of liver disease, variceal hemorrhage, cholecytitis, optic neuritis and anemia requiring transfusion\[^{13,34}\]. The efficacy and the safety of triple therapy have been tested in patients with mildly decompensated cirrhosis as well\[^{35}\]. SVR at 12 wk was achieved by 35% of patients with CP \(\geq 6\) vs 54% of those with CP = 5\[^{35}\]. Furthermore, 25% of patients with compensated cirrhosis discontinued treatment early due to adverse events, while high proportion required drug dose reductions and hospitalizations due to side effects\[^{35}\]. Although a French multicenter phase II trial is being assessing the safety and the efficacy of boceprevir-based triple therapy in patients with genotype 1 and a baseline MELD score 18 on the waiting list\[^{36}\], it is apparent that IFN-free therapies are highly desirable for patients with decompensated disease\[^{34,35}\].

In fact, the treatment chances of critical CHC candidates for LT will be very high should second generation DAAs is applicable. Sofosbuvir, a nucleotide HCV polymerase inhibitor, is now available and offers better tolerability and efficacy across all HCV genotypes making sustained clearance of HCV deliverable to a much larger number of infected individuals\[^{38}\]. We are at the beginning of an era where combinations of DAAs may pave the way for IFN-free regimens, even improving the viral clearance rate to near 100%. Evidence comes from the following four trials\[^{37-40}\]. In the open label phase II study of Curry et al\[^{37}\] 61 CHC candidates with HCC and normal liver function tests (CP score \(\leq 7\)) commenced on sofosbuvir (400 mg/d) and RBV (based on their weight) until LT for a maximum of 48 wk. Thirty six out of the 40 patients who underwent LT achieved viral load below 25 IU/mL before LT. In the view of excellent tolerability, 96% had unidentifiable HCV RNA and no viral recurrence at four weeks post LT. Nevertheless, 69% achieved SVR and 27% had HCV recurrence, 12 wk post LT. Curiously, one patient undergone second LT died and one presented anemia related to RBV.

Given the high mortality due to HCV recurrence after LT, the evidence that sofosbuvir and RBV before LT prevented the recurrence of CHC after LT in 70% of patients who had undetectable HCV RNA prior to LT, provide great hope for patients in need. In the randomized open label study of Afdhal et al\[^{38}\] 50 CHC with genotypes 1-4 either commenced on sofosbuvir plus RBV for 12 mo or were observed for 6 mo and then treated. Patients’ characteristics included portal hypertension plus/minus decompensated liver disease, CP score 5-10 and MELD score > 13. Undetectable HCV-RNA was achieved in 100% for CP class A and 93% for CP class B after 6 mo of treatment. No patient experienced treatment breakthroughs. Ultimately, in the study of Gane et al\[^{39}\] 20 patients with CHC genotype 1 and CP class B received sofosbuvir + RBV combined with the newer NS5A inhibitor ledipasvir for four weeks

### Table 1 Direct acting antivirals commenced on patients with decompensated cirrhosis or recipients after liver transplantation

| Approved protease inhibitors | NS3-4A serine protease inhibitors |
|-----------------------------|----------------------------------|
| Boceprevir                  | N55A inhibitor                   |
| Telaprevir                  | Non-nucleoside NS5B polymerase inhibitor |

| Approved NS5A inhibitors | N55A inhibitor |
|--------------------------|----------------|
| Daclatasvir               | N55A inhibitor |

| Approved NS5B RNA-dependent RNA polymerase nucleotide inhibitor | NS5B RNA-dependent RNA polymerase nucleotide inhibitor |
|------------------------------------------------------------------|-------------------------------------------------------|
| Sofosbuvir                                                        | Sofosbuvir                                             |

Newer DAAs evaluated in combination regimens without Peg-IFN

| Ledipasvir (formerly GS-5885)                                      | N55A inhibitor |
|------------------------------------------------------------------|----------------|
| Ombitasvir (formerly ABT-267)                                     | N55A inhibitor |
| Dasabuvir (formerly ABT-333)                                      | Non-nucleoside NS5B polymerase inhibitor               |

| Peg-IFN: Pegylated interferon                                     |
|------------------------------------------------------------------|-------------------------------------------------------|

### Table 2 Doses of antivirals in liver transplant candidates and recipients

| Peg-IFN-α 2a | 180 μg/wk, subcutaneous | Renal adjustment |
|---------------|-------------------------|------------------|
| Peg-IFN-α 2b | Weight-based 1.5 μg/kg week, subcutaneous | No CNI adjustment |
| Ribavirin     | Weight-based, 1000 mg in patients < 75 kg, 1200 mg in patients ≥ 75 kg, orally twice a day | No CNI adjustment |

| Boceprevir | 800 mg orally three times a day | No renal adjustment |
|------------|--------------------------------|-------------------|
| Telaprevir | 1125 mg orally twice a day | CNI adjustment |
| Sofosbuvir | 400 mg daily, orally | No renal adjustment |
| Daclatasvir | 60 mg daily, orally | No renal adjustment |
| Simeprevir | 150 mg daily, orally | No CNI adjustment |

\[^{1}\]Sofosbuvir only in patients with glomerular filtration rate > 30 mL/min;\n\[^{2}\]Simeprevir should not be given with cyclosporine. CNI: Calcineurin inhibitor; Peg-IFN: Pegylated interferon.
Table 3  Treatment of liver transplant candidates with hepatitis C(46)

| Cirrhosis CP A, all HCV genotypes | Sofosbuvir + RBV until LT | Peg-IFN + RBV + sofosbuvir for 12 wk | RBV + sofosbuvir + daclatasvir for 12 wk |
| Cirrhosis CP B and C, all HCV genotypes | Sofosbuvir + RBV until LT | IFN contraindicated | RBV + sofosbuvir + daclatasvir for 12 wk |

CP: Child-Pugh; HCV: Hepatitis C virus; LT: Liver transplant; RBV: Ribavirin; Peg-IFN: Pegylated interferon.

Table 4  Major studies of interferon-free regimens for treatment of hepatitis C virus positive liver transplant candidates reported in 2014

| Ref. | n | CP score | Antiviral scheme | Virological response |
|------|---|---------|-----------------|---------------------|
| Curry et al(37) | 61 | ≤7 | SOF + RBV for 48 wk or until LT | 69% (12 wk after LT) |
| Gane et al(38) | 20 | 7-9 | SOF + RBV + ledipasvir for 12 wk | 89% (SVR 4 wk) |
| Flamm et al(39) | 108 | Decompensated cirrhosis (range: 7-12) | SOF + RBV + ledipasvir for 12 or 24 wk | 87% and 89%, respectively (SVR 12 wk) |
| Afzhal et al(40) | 50 | 5-10 | SOF + RBV for 48 wk | 100% CP class A |
|         |    |      |                 | 93% CP class B at 24 wk under treatment |

n: Number of patients; CP: Child-Pugh; SOF: Sofosbuvir; RBV: Ribavirin; SVR: Sustained virological response.

(preliminary data for the ongoing Electron Study). High percentage (89%) achieved SVR so far (at four weeks) with good safety and tolerance profile (there were no treatment discontinuations). Similarly, sofosbuvir, ledipasvir and RBV for 3 or 6 mo were well tolerated and resulted in high SVR (87% and 89%, respectively) in 108 patients with decompensated cirrhosis CP class B or C(40). Interestingly, Donato et al(41) reported undetectable HCV RNA for 24 wk after treatment discontinuation in a LT recipient treated prior LT - on the waiting list- over LT and post LT for a total period of 24 wk with the combination of sofosbuvir and RBV (Table 4).

Based on the currently available data, patients with decompensated cirrhosis awaiting LT should be treated with the IFN-free, new generation DAAs, with or without RBV regimens. Although more data are needed about the safety of new DAAs drug combinations in this patient population, it seems that the pharmacokinetics of sofosbuvir and daclatasvir do not appear to change significantly in moderate or severe liver impairment(42), while other new DAAs (simeprevir, asunaprevir) seem to be contraindicated in patients with severe liver impairment (CP class C). On the other hand, sofosbuvir should not be given in patients with GFR ≤ 30 mL/min, but ongoing trials will clarify this better issue. With the objective that newer drug combinations will yield safer and more efficient prevention of HCV recurrence post-LT and the - so far poorly treated - patients with low MELD scores and HCC will benefit most(43), treatment recommendations for LT candidates are updated as below: Patients with conserved liver function (CP class A) in whom the indication is HCC for LT is strongly recommended to be treated with daily weight-based RBV (1000 or 1200 mg in patients < 75 kg or ≥ 75 kg, respectively) and daily sofosbuvir until LT. Otherwise, they should be offered a 12-wk treatment prior to LT with the combination of Peg-IFN, RBV and sofosbuvir or the combination of daily weight-based RBV, daily sofosbuvir and daily daclatasvir(46). Candidates with more advanced decompensated cirrhosis (CP class B and C), should be commenced only in IFN-free regimes; i.e., daily weight-based RBV and daily sofosbuvir for minimization post-LT HCV recurrence; for genotypes 1 to 4 the triple combination of daily weight-based RBV, daily sofosbuvir and daily daclatasvir until LT in experienced centres under close monitoring(46). Both sofosbuvir and daclatasvir do not need dose adjustments in patients with CP class B or C disease. Their most frequently reported side effects were fatigue, headache, nausea and anemia, the latter attributable to the co-administration of RBV(46,43).

HCV positive LT recipients

Reinfection of liver allograft is universal resulting in acceleration of HCV recurrence compared with non-LT patients leading in 70% decumption vs 10% in other immunocompetent groups three years post-transplant(44); graft loss and lower survival rates(45,46). HCV recurrence is the most frequent cause of death and accounts for the two thirds of graft failures in patients transplanted for HCV infection(49). Fibrosing cholestatic hepatitis is the most severe aggressive form of HCV recurrence affecting 5%-8% of LT recipients(47). It is characterized by high viral load levels and extensive dense portal fibrosis extending into the sinusoidal spaces, ductular proliferation, cholestasis and mononuclear inflammation(48). Its prognosis is very poor if recipients do not respond to antiviral treatment (Tables 2 and 5).

Several strategies, including the new generation of antivirals, the optimal donor and the immunosuppressant selection, have been applied to improve outcomes post LT. Negative predictive factors associated with aggressive recurrent HCV infection and graft loss are the high HCV RNA levels in both serum and liver at the time of or early post-LT, female gender and older donor age, steatosis of the graft as well as the degree
of human leukocyte antigen matching of the donor and recipient[49,50]. Moreover, immunosuppressant selection is considered a major factor contributing to acceleration of HCV recurrence. While methyl prednisolone pulses for treatment of acute rejection could drive aggressive HCV recurrence ending up to graft loss, sirolimus could result on HCV RNA elimination without additional antiviral treatment[51,52]. Ultimately, everolimus may offer a benefit for posttransplant HCV-related fibrosis progression[53].

Cyclosporine is considered to have advantage over the other immunosuppressants, because of potential antiviral action (the target protein of cyclosporine, cyclophilin A is involved in the HCV replication)[54]; the enhancement of SVR in LT recipients treated with the dual therapy[55] and the fewer interactions with the triple regimen. Steroid free regimens have been also tried; although they were safe and effective, they did not influence HCV recurrence[56,57]. Nevertheless, many of these issues might have limited impact in the era of the newer DAAs, since the majority of patients with HCV recurrence can effectively be treated.

Preemptive prophylaxis for CHC recurrence post LT is not recommended so far with Peg-IFN-based regimens, because as determined by randomized trials the therapeutic cost is high, tolerability is poor and no additional therapeutic effect is gained[58-60]. Nevertheless, new DAAs clinical application this may change this therapeutic strategy in the near future. The presence of significant fibrosis or portal hypertension one year after transplantation is predictive of rapid disease progression and graft loss, requiring urgent antiviral treatment[51,52].

Fibrosing cholestatic hepatitis and significant fibrosis[63] determined by METAIVIR fibrosis stage 2, and cholestatic hepatitis[63,72]. The results were satisfactory and encouraging[63]. Seven studies[73-79] (including four multicenter) suggested that triple therapy was effective in LT recipients, particularly those experiencing severe recurrence, demonstrating SVR in 50%-91% when administered for 12 to 66 wk (Table 6). One major benefit of the triple therapy was the success in treating recipients with fibrosing cholestatic hepatitis[73]. Nevertheless, serious adverse and few fatal events were recorded. The most common side effect was anaemia (40%-50%) required red blood cell transfusions, erythropoietin and/or RBV dose reduction. The mechanism of anaemia was the combination of hemolysis with suppression of bone marrow. In cirrhotic non-responding patients severe infections have been marked in the context of neutropenia (pneumocystosis, aspergilosis, urinary tract infections and erysipelas have been noted). On this ground, severe liver disease may be a contraindication for triple regimen or may require antibiotic prophylaxis and colony-stimulating factors[74]. Kidney insufficiency has also been reported in 13%-38%[73,74].

Furthermore drug-drug interactions remain a crucial clinical issue. Close monitoring of daily calcineurin inhibitors (CNIs) levels and reduction of CNIs dose was required[80]. CNI trough level is increased when first generation DAAs are initiated because they may inhibit cytochrome P450 3A4 and P-glucoprotein. With boceprevir the average reductions were about 2-fold and telaprevir the average reductions were about 5-fold with cyclosporine and tacrolimus respectively, while

| Table 5  Treatment of hepatitis C virus recurrence post liver transplant |
|-----------------------------------------------|
| IFN-free: Sofosbuvir + RBV (HCV genotype 2 for 12-24 wk); sofosbuvir + daclatasvir ± RBV (HCV genotypes 1, 3-6 for 12-24 wk); sofosbuvir + simeprevir ± RBV (HCV genotypes 1, 4 for 12-24 wk) |
| Fibrosis metavir stage 3-4 | Genotype 2/3 | Genotype 1 |
| IL-28B polymorphism | Peg-IFN plus RBV | Fibrosis metavir stage 2 |
| Fibrosing cholestatic hepatitis | Peg-IFN plus RBV | Predictors of poor response |
| Non responders to previous treatments | Monitor closely Hb, WBC, PLTs CNI levels, renal function | Peg-IFN plus RBV plus boceprevir or telaprevir |
| | Consider | |
| | Administration of blood transfusions, EPO, CSGF | |
| | Decrease of RBV dose | |
| | Renal dose adjustment | |
| | Decrease of CNI dose | |
| IFN: Interferon; RBV: Ribavirin; CNI: Calcineurin inhibitor; HCV: Hepatitis C virus; Peg-IFN: Pegylated interferon; DAA: Direct antiviral agent; WBC: White cells blood count; PLTs: Platelets; EPO: Erythropoietin; CSGF: Granulocyte-colony stimulating factor. |
with telaprevir the interactions were more potent around 3-fold and 23-fold with cyclosporine and tacrolimus respectively[73]. Great attention is needed at the time of DAAs discontinuation, increasing the CNI dose the next day and measuring CNI levels at least every 48 h until steady state to be achieved. mammalian target of rapamycin inhibitors are also metabolized by CYP3A4; the clearance of everolimus was reported to decrease by 55% when boceprevir is commenced[80]. No information on the interactions between mycophenolate mofetil and DAAs is available. In healthy individuals prednisone area under the curve was increased by 22%[81].

So far, triple antiviral therapy with first generation DAAs was less effective in patients with genotype 1a, TT/CT interleukin-28B polymorphism and non responders to previous peg-IFN/RBV regimen[82]. However, the approval of sofosbuvir headed forward the care of naïve and treatment experienced LT recipients with CHC recurrence with excellent tolerability, without interaction with the immunosuppressive regimen and potent antiviral activity across a broad range of HCV genotypes[43,83]. Particularly, in the single-arm open-label pilot study of Samuel et al[83], 40 LT recipients with CHC recurrence after 6 mo of LT treated with sofosbuvir plus RBV for maximum of 6 mo. Thirty-three (83%) patients had genotype 1, 16 (40%) were cirrhotic and 9 (23%) patients were previously on telaprevir or boceprevir combined regimens. All patients (100%) had undetectable HCV RNA after a month of treatment and 70% achieved SVR. Rejection and CNIs dose adjustment were not needed. Only fatigue, anemia, arthralgia and diarrhea were of note. Forns et al[43] demonstrated significant antiviral efficacy associated with disease amelioration in 87 LT recipients (72 (83%) presented HCV genotype 1) with severe CHC recurrence including fibrosing cholestatic hepatitis. Fifty-seven (65%) were treated with sofosbuvir combined only with RBV, while 30 (35%) received additional Peg-IFN for up to 48 wk. SVR at 12 wk was achieved in 47 (54%) of LT recipients treated with sofosbuvir plus RBV and in 40 (44%) of LT recipients treated with sofosbuvir plus RBV plus Peg-IFN. No drug side effects were reported. Importantly, 53 (70%) of patients had improved on treatment, 10 (13%) had stabilized and 13 (17%) died with all deaths attributed to progression of liver disease or associated complications.

More recently, very promising are the IFN-free combinations of sofosbuvir with other novel DAAs with or without RBV after LT (Table 7). Although these new DAAs may have interactions with several drugs, they have no contraindication for CNIs co-administration (only simprevir should not be given with cyclosporine) (Tables 2 and 8). Preliminary data[84-89] showed that they led to excellent on treatment virological response and SVR rates along with minimal adverse effects on difficult to treat LT recipients - those with CHC genotype 1, cirrhosis CP stage B and C as well as previously intolerant or non responsive to IFN therapy. More specifically, sofosbuvir plus simprevir presented 91% SVR in LT recipients with genotype 1[85]; Sofosbuvir and daclatasvir showed 85% on treatment virological response in LT recipients with genotype 1[86] and major clinical improvement in 71% along with HCV RNA < 15 IU/mL in 95% at 12 wk under treatment in LT recipients with fibrosing cholestatic hepatitis[87]; ledipasvir plus sofosbuvir plus RBV presented 96%-98% SVR in LT recipients with CHC recurrence[88].

Ultimately, preliminary data from Coral I study[89] showed breakthrough results in 34 LT recipients with CHC genotype 1 treated for 24 wk with the following four-drug combination: Paritaprevir (potent NS3/4A protease inhibitor identified by AbbVie and Enanta, formerly ABT-267) and Dasabuvir (non-nucleoside NS5B polymerase inhibitor; formerly ABT-333) and RBV. More specifically, 97.1% (33/34) achieved SVR at 4 wk and 97% (33/34) achieved SVR at 12 wk. The regimen was generally well tolerated with 1 patient discontinuing study drug due to adverse events. No deaths, no graft losses, or episodes of rejection were recorded. CNI dosing was manageable over the period of the study (Table 7).

Although data are preliminary, current EASL[6] guidelines recommend the following therapeutic regimens to treat HCV recurrence after LT: sofosbuvir and RBV for LT recipients HCV genotype 2; sofosbuvir and daclatasvir plus/minus RBV for LT recipients HCV genotypes 1, 3-6 and sofosbuvir and simprevir plus/minus RBV for genotypes 1, 4. All regimens should be continued for 12-24 wk and no dose adjustments are required for CNI inhibitors.

### Table 6 Major studies tested the efficacy of first generation direct antiviral agents combined with peg-interferon and ribavirin in liver transplant recipients

| Ref. | Year of publication | No. of patients | Sustained virological response |
|------|-------------------|----------------|-------------------------------|
| Coily et al[83] | 2013 | 37 | 50% (20% for telaprevir and 71% for boceprevir) |
| Pongpapong et al[84] | 2013 | 60 | 56% (67% for telaprevir and 45% for boceprevir) |
| Werner et al[85] | 2012 | 9 | 89% |
| Stravitz et al[86] | 2013 | 122 | 28% |
| Ann Brown et al[87] | 2013 | 46 | 60% |
| Faisal et al[88] | 2014 | 76 | 59.5% |
| Werner et al[89] | 2014 | 14 | 50% |
CONCLUSION

Until 2011, the standard of care treatment for genotype 1 HCV was dual therapy with Peg-IFN and RBV. Unfortunately, the success rate was less than 50%, and treatment was frequently associated with significant toxicity. For this reason, much effort has been invested in the development of new treatment for HCV, leading to the approval of the first generation DAAs. Triple therapy with Peg-IFN, RBV and boceprevir or telaprevir was associated with 68% SVR rates in treatment-naïve patients. Whilst the addition of these first generation DAAs marked a bright new era for the prognosis amelioration of LT candidates and recipients with recurrent HCV, there remains the potential for side effects and drug-drug interactions. During 2014, different IFN-free regimens, combinations of second generations DAAs associated with high SVR rates (>95%), shortened duration courses and relatively few toxicities. However, the efficacy of IFN-free regimens in patients with advanced decompensated cirrhosis waiting for LT is not yet established and their high cost may be the biggest challenge to their implementation worldwide. Immune therapies and therapeutic vaccines are very promising but still in progress. Based on the current related published data and the EASL therapeutic recommendations it was presented the rapidly shifting treatment landscape for CHC LT candidates and recipients. In the context of that treatment decisions continue to be individualized.

REFERENCES

1. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30-S34 [PMID: 12407574 DOI: 10.1053/jhep.2002.36791]
2. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9 [PMID: 14586888 DOI: 10.1053/jlts.2003.50268]
3. Adam R, Del Gaudio M. Evolution of liver transplantation for Hepatitis C and direct acting antivirals

Table 7 Major studies of sofosbuvir with other novel direct antiviral agents with or without ribavirin for treatment of hepatitis C virus positive liver transplant recipients reported in 2014

| Ref.                     | n   | Patient characteristics     | Antiviral scheme                                 | Virological response | SVR  | Duration (wk) |
|-------------------------|-----|------------------------------|--------------------------------------------------|----------------------|------|---------------|
| Pungpapong et al[85]    | 55  | Fibrosis 3-4 (29%)           | SOF + simeprevir ± RBV                           | 98% (EOT)            | 91%  | 12            |
| Leroy et al[85]         | 21  | Fibrosing cholestatic hepatitis | SOF + daclatasvir ± RBV (n = 13)                  | 95% HCV RNA < 15 IU/mL | -    | 24            |
|                         |     |                              | SOF + RBV (n = 6)                                 | 81% were not detectable (at week 12 under treatment) | -    |               |
| Conti et al[85]         | 55  | Fibrosis 3-4 (33%)           | SOF + daclatasvir                                 | 85% (at week 8 under treatment) | -    | 24            |
| Kwo et al[85] (CUPILT)  | 34  | Fibrosing cholestatic hepatitis (7%) | Paritaprevir + ritonavir + ombitasvir + dasabuvir + RBV | 100% (EOT) | 97%  | 24            |
| Reddy et al[85]         | 223 | Fibrosis 0-3, CP A-C         | SOF + ledipasvir                                  | -                    | 96%-98% (CP A: 9% CP B: 83%-85% CP C: 60%-67%) | 12-24 |

n: Number of patients included in the study; RBV: Ribavirin; SOF: Sofosbuvir; EOT: End of treatment; SVR: Sustained virological response; CP: Child-Pugh; HCV: Hepatitis C virus.

Table 8 Major drug-drug interactions of the newer direct acting antivirals for hepatitis C

| DAA                | Co-administration should be avoided |
|--------------------|-------------------------------------|
| Sofosbuvir         | P-glycoprotein inducers              |
|                    | Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin; antimycobacteria: Rifampin, rifabutin, rifapentin; St. John’s wort; HIV drugs: Tipranavir/ritonavir |
| Simeprevir         | Inhibitors or inducers of CYP3A4     |
|                    | Antifungals: Fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole; Antibiotics: Clarithromycin, erythromycin, telithromycin; Dexamethasone; Cicapride; HIV drugs: Cobicistat, efavirenz, delavirdine, etravirine, nevirapine, ritonavir and any HIV protease inhibitor |
| Daclatasvir        | Strong inducers of CYP3A4 and/or P-glycoprotein |
|                    | e.g., phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, dexamethasone; St. John’s wort; HIV drugs: darunavir, lopinavir, etravirine |
| Sofosbuvir/ledipasvir | P-glycoprotein inducers, rosuvastatin, simeprevir |

DAA: Direct acting antiviral; HIV: Human immunodeficiency virus.

Pipili C et al. Hepatitis C and direct acting antivirals
hepatocellular carcinoma. *J Hepatol* 2003; 39: 888-895 [PMID: 14642602 DOI: 10.1016/j.jhep.2003.10.003]

4. *García-Retortillo M*, Forns X, Felix A, Moitinho E, Costa J, Navasa M, Rinola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. *Hepatology* 2002; 35: 680-687 [PMID: 11870384 DOI: 10.1003/j.hep.2002.31773]

5. *Vinaixa C*, Rubin A, Aguiler a V, Berenguer M. Recurrence of hepatitis C after liver transplantation. *Ann Gastroenterol* 2013; 26: 304-313 [PMID: 24716403]

6. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol* 2014; 60: 392-420 [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003]

7. *Alexopoulos A*, Papatheodoris GV. Current progress in the treatment of chronic hepatitis C. *World J Gastroenterol* 2012; 18: 6060-6069 [PMID: 23155334 DOI: 10.3748/wjg.v18.i42.6060]

8. *Gane EJ*, Agarwal K. Direct acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”. *Am J Transplant* 2014; 14: 994-1002 [PMID: 24730431 DOI: 10.1111/ajt.12714]

9. *Herbst DA*, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. *Expert Opin Investig Drugs* 2013; 22: 527-536 [PMID: 23448131]

10. *Roche B*, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. *Liver Int* 2012; 32 Suppl 1: 120-128 [PMID: 22212582 DOI: 10.1111/j.1478-3231.2011.02714.x]

11. Parshutin NP, Korsakov SG. [Comparative analysis of the data of acupuncture electrodiagnosis and hormonal status of women with oligomenorrhea]. *Akush Ginekol (Mosk)* 1990; (6): 26-29 [PMID: 22212585]

12. *Bzowej N*, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment under liver transplantation. *Transplant Proc* 2004; 36: 1355-1357 [PMID: 11267325 DOI: 10.1016/S0041-1345(02)05280-2]

13. *Chalasani N*, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, Martin P, Teperman L, Joo A, Lopez-Talavera JC. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. *Hepatology* 2005; 41: 289-298 [PMID: 15660392 DOI: 10.1002/hep.20560]

14. *Mazzaferro V*, Tagger A, Schiavo M, Regalia E, Pulvirenti A, McHutchison JG, Dusheiko G, Di Bisceglie AM, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. *Expert Opin Investig Drugs* 2014; 23: 527-536 [PMID: 23448131]

15. *Zoulim F*, Aguru A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. *Clin Ther* 2010; 32: 2117-2138 [PMID: 21316532 DOI: 10.1016/S0149-2918(11)00022-1]

16. *Zeuzem S*, Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Snaiikue V, Brass CA, Albrecht JK, Bromwich J. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]

17. *Jacobson IM*, Mchutchison JG, Busheigo G, Di Biscegliel AM, Reddy KR, Bzowej NH, Mcarcellin P, Muir AJ, Ferenci P, Flisik R, George J, Rizzetto M, Shouval D, Sola R, Teg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1102912]

18. *Bacon BR*, Gordon SC, Lawitz E, Marcellin P, Vierling J, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV infection. *N Engl J Med* 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]

19. *Zeuzem S*, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhamann B, Poockos P, Lerg R, Shouval D, Vela R, Hoek V, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Pol R, Picchio G, Beaumont M. Telaprevir for treatment of HCV infection. *N Engl J Med* 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1101966]

20. *Sherman KE*, Flumy SL, Adfal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffmann RS, George S, Wright CJ, Poordad F. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med* 2011; 365: 1014-1024 [PMID: 21916639 DOI: 10.1056/NEJMoa110463]

21. *Joshi D*, Carey I, Agarwal K. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. *Aliment Pharmacol Ther* 2013; 37: 659-671 [PMID: 23433230 DOI: 10.1111/apt.12260]

22. *Hezode C*, Dorival C, Zoulim F: Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 45 cirrhotic non responders. *eLife* 2016. 5: 388-397 [PMID: 27275981]

23. *Ghany MG*, Strader DB, Thomas DL, Seeft LB. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]

24. *Sulkowski MS*, Poordad F, Manns MP, Bromwich JP, Rajender Reddy K, Harrison SA, Adfal NH, Sings HL, Pedicone LD, Koury KJ, Snaiikue V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPIRINT-2) trial. *Hepatology* 2013; 57: 974-984 [PMID: 23081753 DOI: 10.1002/hep.26096]
Pipili C et al. Hepatitis C and direct acting antivirals

33 Poordad F, Lwitz E, Reddy K, Afdaial NH, Hezode C, Zeuzem S, Lee SS, Calleja JL, Brown RS, Craxi A, Wedemeyer H, Deng W, Koury K, Boparai N, Pedicone LD, Burroughs M, Wahil J, Brass CA, Albrecht JK, Sulkowski MS. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. J Hepatol 2012; 56: S549-560 Abstract [DOI: 10.1016/S0168-8278(12)61430-5]

34 Verna EC, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, Fox AN, Dove LM, Brown RS. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver Int 2015; 35: 510-517 [PMID: 24905624]

35 Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monzo A, Terrault NA. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther 2014; 39: 1213-1224 [PMID: 24654657 DOI: 10.1111/apt.12718]

36 French National Agency for Research on AIDS and Viral Hepatitis. Clinical Trial to Evaluate the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01463561 NLM Identifier: NCT01463561

37 Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, O’Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befèler A, Gane E, Saab S, McHutchion JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Mookna D, Afdaial N. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 1007-1017. [PMID: 25261839 DOI: 10.1053/j.gastro.2014.09.023]

38 Afdaial N, Everson G, Callejea J, McCaughan G, Symonds WT, Denning J, McNair L, McHutchison JG, Arterburn S, Charlton M, Reddy R, Asselah T, Gane E, Forns X. Sofosbuvir and ribavirin for the treatment of chronic hepatitis C with cirrhosis and portal hypertension with or without decompensation: early virologic response and safety. J Hepatol 2014; 60: S23 [DOI: 10.1016/S0168-8278(14)60070-2]

39 Gane EJ, Hyland RH, An D, Pang PS, Symonds WT, McHutchison JG, Stedman CA: Sofosbuvir/Ledipasvir fixed dose combination is safe and effective in difficult to treat populations including genotype-3 patients, decompensated type-3 patients and genotype-1 patients with prior sofosbuvir treatment experience. J Hepatol 2014; 60: S1-22 [DOI: 10.1016/S0168-8278(14)60008-8]

40 Flamm S, Everson G, Charlton M, Denning J, Arterburn J, Brandt-Sarif, Pang P, McHutchisonJ, Reddy K, Afdaial N: Ledipasvir/Sofosbuvir with Ribavirin for the treatment of HCV in Patients with Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter study. Hepatology 2014; 60 (Suppl 4): 321A

41 Donato MF, Monico S, Malinverno F, Aghemo A, Maggioni M, Reggiani P, Colombo M. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int 2015; 35: 1-4 [PMID: 25074044 DOI: 10.1111/liv.12646]

42 Lens S, Gambato M, Londoño MC, Forns X. Interferon-free regimens in the liver-transplant setting. Semin Liver Dis 2014; 34: 58-71 [PMID: 24782259 DOI: 10.1055/s-0034-1371011]

43 Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L, Prieto M, Fontana RJ, Baumert TF, Coilly A, Vaghefi P, Adam R, Vittecoq D, Castaigne D, Samuel D, Duclos-Vallée JC. Fibrosing cholestatic hepatitis C in HCV-co-infected transplant patients—usefulness of early markers after liver transplantation. Am J Transplant 2011; 11: 1686-1695 [PMID: 21749638 DOI: 10.1111/j.1600-6143.2011.03660.x]

44 Berenguer M, McCaughan G. Hepatitis C virus-associated cholestatic hepatitis: we cannot seem to agree on diagnostic criteria. Liver Transpl 2013; 19: 115-117 [PMID: 23193777]

45 Di Biscaglia AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Laks A, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-2441 [PMID: 19052125]

46 Di Biscaglia AM, Stoddard AM, Dienstag JL, Shiffman ML, Seef LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011; 53: 1100-1108 [PMID: 21480316 DOI: 10.1002/hep.24169]

47 Manosou P, Samanakis D, Cholongitas E, Patch D, O’Beirne J, Dhillon AP, Rolles K, McCormack A, Hayes P, Burroughs AK. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009; 15: 1783-1791 [PMID: 19938143 DOI: 10.1002/hep.21907]

48 Samanakis DN, Cholongitas E, Triantos CK, Griffiths P, Dhillon AP, Thalheimer U, Patch DW, Burroughs AK. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 2005; 43: 1091-1093 [PMID: 16239045 DOI: 10.1016/j.jhep.2005.08.005]

49 Ganschow R, Pollok JM, Jankovsky M, Junge G. The role of everolimus in liver transplantation. Clin Exp Gastroenterol 2014; 7: 329-343 [PMID: 25214801 DOI: 10.2147/CEG.S41780]

50 Chatterji U, Bobardt M, Selvarajah S, Yang T, Fang H, Sakamoto N, Vaugnias G, Parkison T, Gallay P. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem 2009; 284: 16988-17005 [PMID: 19380579 DOI: 10.1074/jbc.M109.007625]

51 Cescon M, Grazi GL, Cucchietti A, Vetrone G, Ravaioleti M, Ercolani G, Morelli MC, Picaglia F, Tameé M, Pinna AD. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transplant 2009; 15: 782-789 [PMID: 19562715 DOI: 10.1002/hep.21760]

52 Klintrnmal GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecasis M, Mills J, Jennings LW, Faigle CA. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplant 2011; 17: 1384-1403 [PMID: 21850690 DOI: 10.1002/hep.22417]

53 Neumann U, Samuel D, Trunekta P, Gugenheim J, Gerunda GE, Friman S. A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients. J Transplant 2012; 2012: 894215 [PMID: 22690326 DOI: 10.1155/2012/894215]

54 Verna EC, Brown RS. Hepatitis C virus and liver transplantation.
Pipili C et al. Hepatitis C and direct acting antivirals

Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haim-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86 [DOI: 10.1016/j.jhep.2013.08.018]

Pungnapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-706 [DOI: 23066732 DOI: 10.1016/j.it.2013.08.018]

Werner CR. Egetemy DP, Lau R, Nadalin S, Königsrainer A, Malek NP, Berg CP. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy results. Liver Transpl 2012; 18: 1464-1470 [DOI: 22941516 DOI: 10.1002/lt.23542]

Stravitz TLJ, Dodge J, Saxena V, Burton J, Verna E, O’Leary J, Parikh N, Everson G, Brown R, Trotter J, Terrault N: Higher Sustained Virologic Response (SVR-12) Achievable in Liver Transplant (LT) Recipients with Hepatitis C (HCV) Treated with Protease Inhibitor (PI) Triple Therapy (TT). Hepatology 2013; 58 (4 suppl)

Ann Brown R, Russo M, Levitsky J, Yoshida E, Vargas H, Bharat M, Rubin R, Brown R. Twice-daily Telaprevir in combination with Peginterferon alfa 2a/ribavirin in genotype 1 HCV Liver Transplant recipients: interim week 16 Safety and Efficacy Results on the Prospective, Multicenter REFRESH Study. Hepatology 2013; 58: 4

Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, Al-Judaibi B, Renner EL, Lilly LB. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol 2014; 13: 525-532 [DOI: 25152985]

Werner CR, Egetemy DP, Nadalin S, Königsrainer A, Malek NP, Lau R, Berg CP. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Z Gastroenterol 2014; 52: 27-34 [DOI: 24420796 DOI: 10.1055/s-0033-1356345]

Coilley A, Furlan V, Roche B, Barua C, Noël C, Bonhomme-Favre L, Antonini TM, Roque-Afonso AM, Samuel D, Taburet AM, Duclos-Vallée JC. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012; 56: 5728-5734 [DOI: 22908172]

James P. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and prednisolone in healthy volunteers. Hepatology 2012; 56 (SI): 10676A

Coilley A, Roche B, Duclos-Vallée JC, Samuel D. Management of HCV transplant patients with triple therapy. Liver Int 2014; 34 Suppl 1: 46-52 [DOI: 24370378 DOI: 10.1111/lil.12406]

Samuel D, Charlton E, Gane E, Brown JR, Curry M, Kwo P, Fontana R, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Denning J, McNair L, Artibrurn S, Terrault N, Forx S, Manns M. Sofosbuvir plus ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: Results of a prospective, multicenter study. J Hepatol 2014; 60: S49910

Aqel B, Pungnapong S, Werner KT, Chervenak A, Rakela J, Watt K, Leise M, Murphy J, Henry T, Ryland K. The use of Sofosbuvir and Simeprevir to treat HCV G1 in the liver transplant setting: The experience of three transplant settings. Hepatology 2014; 60 (54): 206A

Pungnapong S, Werner KT, Aqel B, Leise M, Murphy J, Henry T, Ryland K, Chervenak A, Watt K, Vargas H, Keaveny A. Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to treat HCV Genotype 1 after Liver Transplantation. Hepatology 2014; 60 (54): 201A

Conti F, Lebray P, Schielke A, Regnaut H, Thabut D, Eyoard Y, Pousoul-Robert A, Chazouillères O, Calmus Y. Sofosbuvir/Daclatasvir therapy for recurrent Hepatitis C after Liver Transplantation:
Preliminary report from the Parisian centers. *Hepatology* 2014; 60 (S4): 208A

87 Leroy V, Dumortier J, Coilly A, Sebag M, Faugerou-Leurent C, Radenne S, Botta D, Dourand F, Silvain C, Lebray P. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV recurrence after liver transplantation: The ANRS study CO23 COPILT study. *Hepatology* 2014; 60 (S4): 207A

88 Reddy K, Everson G, Flamm S, Denning J, Arterburn S, Brandt-Sarif T, Pang P, McHutchison J, Curry M, Charlton M. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: Preliminary results of a prospective multicenter study. *Hepatology* 2014; 60 (S4): 200A

89 Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. *N Engl J Med* 2014; 371: 2375-2382 [PMID: 25386767 DOI: 10.1056/NEJMoa1408921]

**P-Reviewer:** Dang SS, Inoue K, Kapoor S  
**S-Editor:** Ji FF  
**L-Editor:** A  
**E-Editor:** Liu SQ
